USE OF PHOSPHOLIPIDS IN THE TREATMENT OF DEGENERATIVE LUNG DISEASE AND TO ENHANCE DELIVERY OF DRUGS

摘要

Surface active phospholipid (SAPL) is administered as a dry powder for the treatment of neutrophil-induced or irreversible degenerative lung disease, especially chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). The SAPL powder is also used in combination therapy to enhance the delivery of biologically active substances to airways to treat COPD and CF, and to enhance the delivery of other actives via mucosal membranes.